Harbin Jixianglong Biotech recalls
FDA enforcement reports naming Harbin Jixianglong Biotech Co., Ltd. as the recalling firm.
- Recall reports
- 2
- Class I (serious)
- 0
- Most recent report
- Mar 11, 2026
- Mar 11, 2026Semaglutide, For Rx compounding use only, packaged in a) 1gDrug · Harbin Jixianglong Biotech Co., Ltd.CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distributionClass II
- Mar 11, 2026Semaglutide, For Rx compounding use only, packaged in a) 1gDrug · Harbin Jixianglong Biotech Co., Ltd.CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distributionClass II